• Anna Smith
• 22 Jul, 2019

Merck and Pfizer have announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has issued an Early Access to Medicines Scheme (EAMS) positive scientific opinion for Bavencio (avelumab) used in combination with Inlyta (axitinib). The opinion is for the combination as first-line treatment of adult patients with advanced renal cell carcinoma (RCC),
Read more...